Commercialization And Logistics

31. Ensure Consistency Across Batches With A Powerful Tool 5/19/2025

    Learn how to streamline bioprocess control with an innovative software's Unit Save and Load feature. Save configurations, reduce setup time, and ensure consistency across batches with this powerful tool.

32. Regulatory Compliance And Viral Vectors 11/13/2023

    Hear from experts who detail the specific regulatory challenges for advanced therapies, as well as how the regulatory requirements differ in early research and development in academia and in industrial vector production.

33. mRNA For Cancer Immunotherapy 2024 Outlook | Audience Q&A 1/29/2024

    During our Cell & Gene Live, mRNA For Cancer Immunotherapy 2024 Outlook, our expert panelists answered audience questions regarding patient safety, foreseeable challenges in mRNA cancer immunotherapy for solid tumors, and much more.

34. Technology Needs For Automated Manufacturing 8/18/2023

    Investigate the importance of technology as it relates to automation and standardization within cell therapy manufacturing. The panelists in this discussion cover solutions and services needed for process automation in CGT.

35. Supply Chain And Operational Challenges Facing mRNA 1/29/2024

    Explore some of the biggest supply chain challenges facing mRNA cancer therapeutics and what short-term solutions may exist, starting with Chain of Custody/Chain of Identity.

36. Manufacturing Hurdles With Viral Vectors 11/13/2023

    With a wide range of viral vector-based drugs already approved, viral vectors are expected to remain the primary delivery mechanism for the foreseeable future. However, as the demand for viral vectors increases, addressing the challenges related to their manufacture and scale-up is critical. In this segment, Dave Maheu, VP, Head of Process & Analytical Development at Candel Therapeutics and Curran Simpson, Chief Operating Officer at REGENXBIO share what they consider to be the most difficult challenges in vector development and manufacturing currently.

37. Collaborating with the FDA: Dr. Peter Marks and Dr. Nicole Verdun Share Advice For Small And Emerging Biotechs 1/30/2024

    In this segment, Dr. Peter Marks and Dr. Nicole Verdun share their advice and best practices for small and emerging biotechs when working with the FDA.

38. Scalable Purification Of In Vitro Transcribed mRNA 6/24/2025

    Learn more about how affinity-based mRNA chromatography resin facilitates the purification and isolation of mRNA from in vitro transcription (IVT) manufacturing processes.

39. Tailoring Purification Solutions To Address Customer Challenges 5/21/2025

    Developing purification products for novel biotherapeutics requires close customer collaboration to ensure the tools do the job. Hear how these partnerships drive targeted innovation.

40. Advancing Gene Therapy Development With A Multi-Serotype AAV Resin 5/29/2025

    In this webinar, leading CDMO ABL and Thermo Fisher will share data on implementation of the POROS™ CaptureSelect™ AAVX affinity resin into such an AAV purification platform, including its performance in purifying several serotypes.